Jiuan Medical Investment: "Konomi" Completes Tens of Millions of Yuan Series A+ Round Financing | Exclusive Report by 36Kr
36Kr learned that Konorma (Beijing) Technology Co., Ltd. (hereinafter referred to as "Konorma"), a high - end scientific instrument manufacturer, has completed tens of millions of yuan in Series A+ financing. This round of financing was invested by iHealth, and the raised funds will be used for accelerating commercial layout, continuous innovation in independent R & D, etc.
Relevant data shows that the Chinese analytical instrument market is highly dependent on imports, with an annual import value of about 100 billion US dollars. Among them, liquid chromatography, as a basic equipment in fields such as chemical analysis, life sciences, and clinical testing, is the "top - selling single product". However, with the wave of "domestic substitution" in recent years, a number of startups in this field have emerged in China.
Konorma is one of them. The company was founded in 2019 and focuses on the independent R & D and industrialization of ultra - high - performance liquid chromatography (UHPLC) technology. The core founding team has an average of nearly 20 years of work experience in the life science instrument field, and nearly 30% of the company's employees are in R & D and technical positions. As of April 2025, Konorma has applied for more than 30 patents and software copyrights in total, including 6 invention patents, 14 utility model patents, and a number of proprietary technologies.
It is reported that Konorma has now completed the "full - range layout" of ultra - high - performance liquid chromatography products and created a full - process, exclusive and customized solution covering the fully automatic IVD two - dimensional liquid chromatography system, fully automatic biological sample pretreatment platform, EyouLab CDS intelligent chromatography data management system, and supporting reagents and consumables.
Notably, in 2025, the company launched the upgraded ultra - high - pressure binary pump UP26T (made of titanium alloy biocompatible material) and the quaternary pump UP40 again. The pressure resistance has exceeded 20,000 Psi (1380 Bar). Its titanium alloy material is biocompatible and provides ideal front - end support for mass spectrometry coupling systems.
In terms of production capacity and supply chain, in 2022, Konorma started the construction of its production base in Suzhou, which has a production and assembly workshop, a GMP - grade reagent production workshop, a production planning department, a quality control center, a warehouse, etc. At present, the localization rate of the company's product components has reached 95%.
Data provided by Konorma shows that since the start of the commercial layout in 2023, the company's annual sales growth rate has continuously exceeded 50%, and the average annual growth rate in the overseas market has exceeded 80%. It has covered hundreds of customers in more than 20 countries and regions around the world, covering fields such as pharmaceutical analysis, biosynthesis, academic research, food safety, and environmental protection.
"On the one hand, through the localization of high - end equipment, we help customers significantly reduce procurement costs and improve analysis efficiency; on the other hand, relying on diversified and customized solutions to continuously expand technology application scenarios, we effectively reduce customers' dependence on the supply chain and procurement channels of imported products, and promote the construction of an independent and controllable industry supply chain." Zhang Xin, co - founder and CEO of Konorma, said.
Investor's view:
Liu Yi, the chairman of iHealth, said that iHealth is committed to discovering and collaborating with practical enterprises that can solve industry pain points and lead industrial upgrading. Compared with simple capital injection, iHealth focuses on two core opportunities: one is to deepen the "Stanford model" around independent R & D, fully activate the "engineer dividend", and transform the talent advantage into the driving force for technological breakthroughs; the other is to seize the wave of localization of scientific instruments and policy support, root in China's efficient supply chain, promote import substitution in the global market, and achieve cross - cycle growth. Konorma is exactly such a company. Its in - depth exploration and breakthroughs in the field of ultra - high - performance liquid chromatography have broken the long - term dependence of the high - end market in this field in China on imports.